A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Title

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)

Authors

Keywords

Bevacizumab, Non-small-cell lung cancer, Epidermal growth factor receptor mutation, Second-line, Carboplatin, Paclitaxel

Journal

LUNG CANCER

Volume 87, Issue 2, Pages 136-140

Publisher

Elsevier BV

Online

2014-12-20

DOI

10.1016/j.lungcan.2014.12.007